TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31912791

Group type: EXPERIMENTAL
Intervention: Vemurafenib (960 mg twice daily for 52 weeks)
Number of subjects: 498

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 498
Study: 31672941

Group type: EXPERIMENTAL
Intervention: Intralipid infusion
Number of subjects: 17

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 17
Study: 28013376

Group type: EXPERIMENTAL
Intervention: High-vacuum wound drainage system
Number of subjects: 1424

Group type: COMPARATOR
Intervention: Open incision and drainage (I&D)
Number of subjects: 1424
Study: 25205417

Group type: EXPERIMENTAL
Intervention: Web-based intervention to promote appropriate gestational weight gain
Number of subjects: 873
Study: 23408069

Group type: EXPERIMENTAL
Intervention: Strata shunt with valve preset at performance level (PL) 2.5, allowed to be lowered until improvement or radiological signs of overdrainage were met.
Number of subjects: 58

Group type: COMPARATOR
Intervention: Strata shunt with valve preset at performance level (PL) 1.0 (control group).
Number of subjects: 58
Study: 22089718

Group type: EXPERIMENTAL
Intervention: Evacetrapib monotherapy, 30 mg/d
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Evacetrapib monotherapy, 100 mg/d
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Evacetrapib monotherapy, 500 mg/d
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Statin therapy (simvastatin 40 mg/d, atorvastatin 20 mg/d, or rosuvastatin 10 mg/d) with evacetrapib, 100 mg/d
Number of subjects: 398

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 398

Group type: COMPARATOR
Intervention: Statin monotherapy
Number of subjects: 398
Study: 19812027

Group type: EXPERIMENTAL
Intervention: Dentist intervention (n = 44)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: School nurse intervention (n = 42)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group (n = 39)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Diurnal types (morning types)
Number of subjects: 127
Study: 16381016

Group type: EXPERIMENTAL
Intervention: 9 cycles of tailored and dose-escalated FEC (5-fluorouracil, epirubicin, cyclophosphamide)
Number of subjects: 118

Group type: COMPARATOR
Intervention: 3 cycles of standard FEC followed by high-dose chemotherapy
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Monitoring BM changes at diagnosis and 6 months post-treatment
Number of subjects: 118
Study: 16647907

Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride, 60 mg once daily
Number of subjects: 43

Group type: COMPARATOR
Intervention: Alendronate, 10 mg daily
Number of subjects: 43
Study: 14659350

Group type: EXPERIMENTAL
Intervention: Familial and hormonal risk factors for breast cancer, including lower body mass index and nulliparity.
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Changes in breast density as a potential early indicator of efficacy in chemoprevention trials for breast cancer.
Number of subjects: 102
Study: 10337502

Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine (1 g three times a day orally for 90 days)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 7478455

Group type: EXPERIMENTAL
Intervention: Local application of tranexamic acid gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1937991

Group type: EXPERIMENTAL
Intervention: Hypnosis intervention
Number of subjects: 36

Group type: COMPARATOR
Intervention: Usual care (no hypnosis)
Number of subjects: 36
Study: 6957978

Group type: EXPERIMENTAL
Intervention: Pirenzepine 25 mg b.i.d.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Pirenzepine 50 mg b.i.d.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Pirenzepine 50 mg t.d.s.
Number of subjects: 11

Group type: COMPARATOR
Intervention: No drug (control)
Number of subjects: 11
Study: 29631106

Group type: EXPERIMENTAL
Intervention: High-protein supplementation (36% protein in total calorie)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Low-protein control supplementation (12% protein in total calorie)
Number of subjects: 15
Study: 27424464

Group type: EXPERIMENTAL
Intervention: Auditory stimulation integrated into the RehaCom program of attention training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no attention training)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Attention training
Number of subjects: 20
Study: 25690514

Group type: EXPERIMENTAL
Intervention: Liberal RBC transfusion strategy (hemoglobin <11.3 g/dL; 7 mmol/L)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Restrictive RBC transfusion strategy (hemoglobin <9.7 g/dL; 6 mmol/L)
Number of subjects: 284
Study: 22955567

Group type: EXPERIMENTAL
Intervention: Nicotine patches
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 24
Study: 20668005

Group type: EXPERIMENTAL
Intervention: CD8+ enriched young TIL and IL-2 after NMA
Number of subjects: 56

Group type: COMPARATOR
Intervention: CD8+ enriched young TIL and IL-2 after NMA and 6 Gy total body irradiation
Number of subjects: 56
Study: 18434566

Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg twice a day
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg every day
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice a day
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 17060040

Group type: EXPERIMENTAL
Intervention: NNECVDSG score tertiles
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: McSPI score tertiles
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Extracardiac arteriopathy
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Urgent/emergency operation
Number of subjects: 241
Study: 12612228

Group type: EXPERIMENTAL
Intervention: Interactive Multimedia Program for Asthma Control and Tracking
Number of subjects: 228

Group type: COMPARATOR
Intervention: Traditional patient education
Number of subjects: 228
Study: 10990051

Group type: EXPERIMENTAL
Intervention: Grid pattern laser photocoagulation plus arterial crimping (group B)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Grid pattern laser photocoagulation alone (group A)
Number of subjects: 72
Study: 9374590

Group type: EXPERIMENTAL
Intervention: Patients with sharp bend curves
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with intermediate forms of flow-volume curves
Number of subjects: 0
Study: 1283476

Group type: EXPERIMENTAL
Intervention: GHRH + galanin (500 micrograms in 100 ml saline)
Number of subjects: 14

Group type: COMPARATOR
Intervention: GHRH + saline (100 ml)
Number of subjects: 14
Study: 2413379

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (vinblastine 6 mg/m2 i.v., bleomycin 15 mg i.m., methotrexate 40 mg/m2 i.v., cyclophosphamide 400 mg/m2 i.v., 5-fluorouracil 5 mg/kg i.v.)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Conventional treatment only
Number of subjects: 68
Study: 29884413

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks
Number of subjects: 361

Group type: COMPARATOR
Intervention: Investigator's choice (IC)
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 361
Study: 27611751

Group type: EXPERIMENTAL
Intervention: Metal-Ceramic Fixed Dental Prosthesis (MC-FDP)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: All-Ceramic Fixed Dental Prosthesis (AC-FDP)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control Group (Fully Dentate, n=20)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Patients' Satisfaction
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Professionals' Esthetic Evaluation
Number of subjects: 34
Study: 24071935

Group type: EXPERIMENTAL
Intervention: Pilates, McKenzie and Heckscher training (group I)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Classical kinetic program (group II)
Number of subjects: 96
Study: 22262728

Group type: EXPERIMENTAL
Intervention: Web-based diabetes-specific cognitive behavioral therapy (CBT) for depression, with minimal therapist support, delivered over 8 lessons.
Number of subjects: 255

Group type: COMPARATOR
Intervention: Waiting-list control group for 12 weeks.
Number of subjects: 255
Study: 20035979

Group type: EXPERIMENTAL
Intervention: Pelvic reduction during pyeloplasty
Number of subjects: 42

Group type: COMPARATOR
Intervention: Pelvis-sparing pyeloplasty
Number of subjects: 42
Study: 17663804

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (4.4 ml/d)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: High 18: 2n‐6 intake (R/K group)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Low 18: 2n‐6 intake (S/B group)
Number of subjects: 64
Study: 15641055

Group type: EXPERIMENTAL
Intervention: Combination of disease-modifying antirheumatic drugs (DMARDs) with prednisolone
Number of subjects: 195

Group type: COMPARATOR
Intervention: Single DMARD with or without prednisolone
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: ACR50 response
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: ACR20 response
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: No ACR20 response
Number of subjects: 195
Study: 12932590

Group type: EXPERIMENTAL
Intervention: AAIR pacing
Number of subjects: 177

Group type: COMPARATOR
Intervention: DDDR pacing with short AV delay (DDDR-s)
Number of subjects: 177

Group type: COMPARATOR
Intervention: DDDR pacing with long AV delay (DDDR-l)
Number of subjects: 177

Group type: COMPARATOR
Intervention: DDDR pacing (both DDDR-s and DDDR-l)
Number of subjects: 177
Study: 10550443

Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Ibandronate (2.5 mg)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study: 9110066

Group type: EXPERIMENTAL
Intervention: Retinal photography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Funduscopy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined approach (retinal photography and funduscopy)
Number of subjects: 0
Study: 1672539

Group type: EXPERIMENTAL
Intervention: Somatostatin (ST)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Balloon Tamponade (BT)
Number of subjects: 44
Study: 6749526

Group type: EXPERIMENTAL
Intervention: Tolbutamide 0.5 g administered 30 min prior to a standardized meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tolbutamide 0.5 g administered immediately before a standardized meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo administered with a standardized meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tolbutamide 0.5 g with the meal
Number of subjects: 0
Study: 31221158

Group type: EXPERIMENTAL
Intervention: mCNCP
Number of subjects: 101

Group type: COMPARATOR
Intervention: pCNCP
Number of subjects: 101
Study: 29945500

Group type: EXPERIMENTAL
Intervention: Non-hydroxamate HDAC6 inhibitors identified through pharmacophore modeling and molecular docking.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacophore model (Hypo1) generated from 26 training set compounds.
Number of subjects: 0
Study: 26576715

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide in addition to furosemide regimen
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo in addition to furosemide regimen
Number of subjects: 304
Study: 25325773

Group type: EXPERIMENTAL
Intervention: Long-lever posterior-tilt plank
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Long-lever plank
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Posterior tilt plank
Number of subjects: 19

Group type: COMPARATOR
Intervention: Traditional prone plank
Number of subjects: 19
Study: 22840666

Group type: COMPARATOR
Intervention: Higher placebo adherence (≥75% adherence)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Lower placebo adherence (<75% adherence)
Number of subjects: 1000
Study: 19800084

Group type: EXPERIMENTAL
Intervention: Berberine (BBR)
Number of subjects: 0
Study: 18058596

Group type: EXPERIMENTAL
Intervention: Insulin glargine plus glimepiride (Group A; n=17)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Insulin glargine plus glimepiride and metformin (Group B; n=18)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Premixed insulin (Group C; n=17)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 52
Study: 16173134

Group type: EXPERIMENTAL
Intervention: Fumaria officinalis 1500 mg daily (fumitory group)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Curcuma xanthorriza 60 mg daily (curcuma group)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 11868058

Group type: EXPERIMENTAL
Intervention: tranilast (600 mg/day for 3 months)
Number of subjects: 297

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: tranilast (in restenotic lesions)
Number of subjects: 297
Study: 10379748

Group type: EXPERIMENTAL
Intervention: Transurethral needle ablation
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Prostate resection
Number of subjects: 121
Study: 8882259

Group type: EXPERIMENTAL
Intervention: ketorolac 10 mg
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: lignocaine 10 mg
Number of subjects: 101

Group type: COMPARATOR
Intervention: saline
Number of subjects: 101
Study: 1948092

Group type: EXPERIMENTAL
Intervention: 40 mg SSHA (administered daily for 11 days, with 40 mg SC administered three times every 90 min on the first day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10, 20, 40, and 70 mg SSHA (dose-dependent effect tested)
Number of subjects: 12
Study: 6656240

Group type: EXPERIMENTAL
Intervention: alpha-methyldopa
Number of subjects: 6

Group type: COMPARATOR
Intervention: HPLC
Number of subjects: 6

Group type: COMPARATOR
Intervention: THI-fluorometric method
Number of subjects: 6
Study: 30861098

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 299

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study: 28714563

Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA for 20 min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0
Study: 27498662

Group type: EXPERIMENTAL
Intervention: Dr. Michaels® product family (Soratinex®)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Methylprednisolone aceponate (MPA)
Number of subjects: 30
Study: 24994842

Group type: EXPERIMENTAL
Intervention: Standard and new antiepileptic drugs (monotherapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: First treatment failure
Number of subjects: 0
Study: 22813445

Group type: EXPERIMENTAL
Intervention: Buspirone (10 mg, 3 times daily for 4 weeks)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 21122491

Group type: EXPERIMENTAL
Intervention: 4g enema administered daily (Group A, 15 pts)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 4g enema administered every 2 days (Group B, 15 pts)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 4g enema administered every 3 days (Group C, 15 pts)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Oral Mesalazine treatment alone (OT)
Number of subjects: 45
Study: 18047869

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 38

Group type: COMPARATOR
Intervention: Diphenhydramine (active placebo)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Amitriptyline vs Gabapentin
Number of subjects: 38

Group type: COMPARATOR
Intervention: Amitriptyline vs Diphenhydramine
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Amitriptyline, Gabapentin, Diphenhydramine
Number of subjects: 38
Study: 16127749

Group type: EXPERIMENTAL
Intervention: Capsaicin (1-8 microg/mL, 100 mL)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Capsaicin (3x400 microg i.g. for two weeks)
Number of subjects: 84
Study: 12359649

Group type: EXPERIMENTAL
Intervention: Exposure to dust or fumes
Number of subjects: 2819
Study: 11464575

Group type: EXPERIMENTAL
Intervention: rhFSH alone (group F)
Number of subjects: 28

Group type: COMPARATOR
Intervention: rhFSH + rhLH (group L)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Subgroup of group L (previous ART cycle with FSH only)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional IVF cycles
Number of subjects: 28
Study: 9677108

Group type: EXPERIMENTAL
Intervention: Closed dressings (single‐ or 3‐layer composite foam, plastic mesh, hydrogel, or polymer film)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Closed dressings
Number of subjects: 40

Group type: COMPARATOR
Intervention: Historical control (open dressings)
Number of subjects: 40
Study: 8021637

Group type: EXPERIMENTAL
Intervention: Intensive psychodynamically and group-oriented program
Number of subjects: 165
Study: 2684441

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60
Study: 5923

Group type: EXPERIMENTAL
Intervention: IV lorazepam (4 mg) plus IM meperidine (50 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: IV placebo plus IM meperidine (50 mg)
Number of subjects: 40
Study: 6987032

Group type: EXPERIMENTAL
Intervention: Phenformin (50 mg)
Number of subjects: 0
Study: 30575237

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) non-adherent behaviors (eg, confronting, persuading)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Lower patient self-efficacy for diabetes self-management
Number of subjects: 55
Study: 30208866

Group type: EXPERIMENTAL
Intervention: Durvalumab (5 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Durvalumab (10 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Durvalumab (20 mg)
Number of subjects: 12
Study: 26235468

Group type: EXPERIMENTAL
Intervention: miTLIF
Number of subjects: 50

Group type: COMPARATOR
Intervention: coPLIF
Number of subjects: 50
Study: 24810796

Group type: EXPERIMENTAL
Intervention: Atropine administration without prior oxygen
Number of subjects: 1957

Group type: EXPERIMENTAL
Intervention: Atropine administration
Number of subjects: 1957
Study: 21945866

Group type: EXPERIMENTAL
Intervention: lipid emulsion, LE (15 g Fabuless, containing 4.2g lipid, 0.2 MJ)+water
Number of subjects: 18

Group type: COMPARATOR
Intervention: lipid control, LC (15 g non‐emulsified lipid/water, containing 4.2g lipid, 0.2 MJ)+water
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: lipid emulsion+yoghurt, LE+Y (1.2 MJ)
Number of subjects: 18

Group type: COMPARATOR
Intervention: lipid control+yoghurt, LC+Y (1.2 MJ)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: lipid emulsion+muffin, LE+M (1.2 MJ)
Number of subjects: 18

Group type: COMPARATOR
Intervention: lipid control+muffin, LC+M (1.2 MJ)
Number of subjects: 18
Study: 20414715

Group type: EXPERIMENTAL
Intervention: Modular treatment in clinic settings
Number of subjects: 139

Group type: COMPARATOR
Intervention: Modular treatment in community settings
Number of subjects: 139
Study: 17630869

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 15310747

Group type: EXPERIMENTAL
Intervention: High-fat, low-carbohydrate diet (HF/LC; 5% carbohydrate, 73% fat, and 22% protein)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-fat, low-carbohydrate diet (HF/LC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet (Con; 51% carbohydrate, 29% fat, and 20% protein)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet (Con)
Number of subjects: 0
Study: 11943438

Group type: EXPERIMENTAL
Intervention: Antiretroviral drug A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiretroviral drug B
Number of subjects: 0
Study: 12198781

Group type: EXPERIMENTAL
Intervention: Ehrenstein figures with varying contrast polarity and inducer spacing
Number of subjects: 0
Study: 8602629

Group type: EXPERIMENTAL
Intervention: GM‐CSF 250 microg/m2 subcutaneously every 12 hr after each course of DICEP until recovery of ANC of 1.5 x 10(9)/L
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo subcutaneously every 12 hr after each course of DICEP until recovery of ANC of 1.5 x 10(9)/L
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: GM‐CSF 250 microg/m2
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 1761663

Group type: EXPERIMENTAL
Intervention: Delayed administration of human chorionic gonadotrophin (HCG) by 24 hours in 96 patients.
Number of subjects: 143

Group type: COMPARATOR
Intervention: Standard administration of human chorionic gonadotrophin (HCG) in 47 patients when the three largest follicles were >= 17 mm.
Number of subjects: 143
Study: 7080505

Group type: EXPERIMENTAL
Intervention: Hexoprenaline (beta‐2‐selective bronchodilator) in paediatric syrup form, dosage not specified, duration not specified
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measurement of obstruction using optimal body plethysmography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-flow curve analysis
Number of subjects: 0
Study: 31823222

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 4 weeks (q4w)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Dupilumab 200 or 300 mg every 2 weeks (q2w)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study: 31062455

Group type: EXPERIMENTAL
Intervention: Computerised cognitive training (8-week intervention period)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Delayed intervention group (control)
Number of subjects: 40
Study: 30596775

Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine (IIV)
Number of subjects: 155
Study: 27374753

Group type: EXPERIMENTAL
Intervention: Affective messages (N = 300)
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Instrumental messages (N = 238)
Number of subjects: 1065

Group type: COMPARATOR
Intervention: No messages (N = 521)
Number of subjects: 1065
Study: 25028506

Group type: EXPERIMENTAL
Intervention: Transdermal 4-hydroxytamoxifen gel (4-OHT) 4 mg/day
Number of subjects: 27

Group type: COMPARATOR
Intervention: Oral tamoxifen (oral-T) 20 mg/day
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Transdermal 4-hydroxytamoxifen gel (4-OHT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Oral tamoxifen (oral-T)
Number of subjects: 27
Study: 22656335

Group type: EXPERIMENTAL
Intervention: Zinc (10 mg orally daily)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700